Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald A Berry

Showing results (61-70 of 197) with videos related to

Pageof 20
Sort By:
Genetics|June 20, 2002
Assessing probability of ancestry using simple sequence repeat profiles: applications to maize hybrids and inbredsDonald A Berry, Jon D Seltzer, Chongqing Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2012
Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009Filip Janku, Donald A Berry, Jing Gong, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's diseaseAndrew Satlin, Jinping Wang, Veronika Logovinsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
Reply to V. Amoroso et alLawrence N Shulman, Donald A Berry, Constance T Cirrincione, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2015
Advancing Clinical Trials to Streamline Drug DevelopmentSusan E Bates, Donald A Berry, Sanjeeve Balasubramaniam, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2007
Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysisJean-Louis Pujol, Sofia Paul, Nadia Chouaki, et al.
Journal of the National Cancer Institute|August 18, 2005
Role of detection method in predicting breast cancer survival: analysis of randomized screening trialsYu Shen, Ying Yang, Lurdes Y T Inoue, et al.
Plos One|December 28, 2020
A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidatesDonald A Berry, Scott Berry, Peter Hale, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 17, 2008
Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experienceWenli Dong, Donald A Berry, Therese B Bevers, et al.
Journal of the National Cancer Institute. Monographs|October 13, 2006
Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approachDonald A Berry, Lurdes Inoue, Yu Shen, et al.
Pageof 20

Showing results (61-70 of 197) with videos related to

Sort By:
Pageof 20
Genetics|June 20, 2002
Assessing probability of ancestry using simple sequence repeat profiles: applications to maize hybrids and inbredsDonald A Berry, Jon D Seltzer, Chongqing Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2012
Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009Filip Janku, Donald A Berry, Jing Gong, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's diseaseAndrew Satlin, Jinping Wang, Veronika Logovinsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
Reply to V. Amoroso et alLawrence N Shulman, Donald A Berry, Constance T Cirrincione, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2015
Advancing Clinical Trials to Streamline Drug DevelopmentSusan E Bates, Donald A Berry, Sanjeeve Balasubramaniam, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2007
Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysisJean-Louis Pujol, Sofia Paul, Nadia Chouaki, et al.
Journal of the National Cancer Institute|August 18, 2005
Role of detection method in predicting breast cancer survival: analysis of randomized screening trialsYu Shen, Ying Yang, Lurdes Y T Inoue, et al.
Plos One|December 28, 2020
A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidatesDonald A Berry, Scott Berry, Peter Hale, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 17, 2008
Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experienceWenli Dong, Donald A Berry, Therese B Bevers, et al.
Journal of the National Cancer Institute. Monographs|October 13, 2006
Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approachDonald A Berry, Lurdes Inoue, Yu Shen, et al.
Pageof 20